Search Results for "meetings"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for meetings. Results 91 to 100 of 170 total matches.
Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015 (Issue 1472)
to imiglucerase in the percentage of
patients meeting the primary endpoint (85% vs 94%,
respectively).4
ADVERSE ...
The FDA has approved eliglustat (Cerdelga –
Genzyme), an oral glucosylceramide synthase inhibitor,
for treatment of adults with type 1 Gaucher disease.
Eliglustat is metabolized primarily by CYP2D6. Because
patients who are CYP2D6 ultra-rapid metabolizers may
not achieve therapeutic concentrations and a specific
dosage cannot be recommended for indeterminate
metabolizers, the FDA has approved the drug only
for patients who are extensive, intermediate, or poor
metabolizers of CYP2D6.
FDA Authorizes Johnson & Johnson COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
for
the prevention of COVID-19. Vaccines and Related Biological
Products Advisory Committee meeting. February 26 ...
On February 27, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the Johnson & Johnson
adenovirus-based vaccine for prevention of COVID-19
in persons ≥18 years old. It is the third COVID-19
vaccine to become available in the US and the first to
require only a single dose. Two-dose mRNA-based
vaccines manufactured by Pfizer-BioNTech and
Moderna received EUAs in December 2020.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022 (Issue 1646)
Meeting. February 4,
2022. Available at: https://bit.ly/3IxhPjZ. Accessed March 3,
2022.
3. SA Buchan ...
The CDC has issued new guidance allowing for
an interval of up to 8 weeks between the first and
second primary doses of an mRNA COVID-19 vaccine
in certain patients 12-64 years old.1 Product labeling
currently recommends a 3-week interval between the
first two doses of the Pfizer/BioNTech mRNA vaccine
(Comirnaty) and a 4-week interval between the first
two doses of the Moderna mRNA vaccine (Spikevax).
The new guidance is based on data suggesting that
a longer interval can decrease the risk of myocarditis
and may improve vaccine efficacy.
H. Influenzae Vaccine For Infants
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991 (Issue 836)
Santosham et al, FDA Vaccines
and Related Biological Products Advisory Committee, public meeting, Aug 20 ...
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
Ziprasidone (Geodon) For Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001 (Issue 1106)
mg b.i.d. (G Simpson et al, abstract NR252 and poster presented at the Annual
Meeting ...
Ziprasidone (Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
Problems With Dietary Supplements
The Medical Letter on Drugs and Therapeutics • Sep 30, 2002 (Issue 1140)
dietary supplements that meet the same Good Manufacturing Practices (GMPs) used to prepare prescription ...
Millions of people now take herbal products and other "dietary supplements." The Physicians' Desk Reference has published a PDR for Herbal Medicines listing their ingredients and indications, and the Drug Topics Red Book lists their prices.
Lowering Plasma Homocysteine
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
Coronary Intervention Trial [FACIT], Am Coll
Cardiol 52
nd
Annual Meeting, 2003). A 2-year open-label ...
High plasma homocysteine concentrations, like high cholesterol, have been associated with an increased risk of cardiovascular disease and death (O Nygσrd et al, N Engl J Med 1997; 337:230; RS Vasan et al, JAMA 2003; 289:1251). In one meta-analysis, 25% lower plasma homocysteine concentrations were associated with 11% less coronary heart disease and 19% less stroke (Homocysteine Studies Collaboration, JAMA 2002; 288:2015). Should we be trying to lower serum homocysteine concentrations in our patients?
Vilazodone (Viibryd) - A New Antidepressant
The Medical Letter on Drugs and Therapeutics • Jul 11, 2011 (Issue 1368)
meeting of the American Psychiatric Association, New
Orleans, LA, May 2010.
7. CD Chambers et al ...
Vilazodone (Viibryd – Forest), a selective serotonin
reuptake inhibitor (SSRI) and partial 5-HT1A receptor
agonist, has been approved by the FDA for treatment
of depression. It has been claimed to have no sexual
side effects and not to cause weight gain.
Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
study. Presented at the 73rd Annual Meeting of the
American Academy of Dermatology, San Francisco ...
The FDA has approved Enstilar (Leo), an aerosol
foam formulation of the synthetic vitamin D3 analog
calcipotriene and the high-potency corticosteroid
betamethasone dipropionate, for topical treatment
of plaque psoriasis in adults. Topical ointment and
suspension formulations of the same combination
have been available for many years.
BioThrax and Anthrasil for Anthrax
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
Control and Prevention
expert panel meetings on prevention and treatment of anthrax
in adults. Emerg ...
The FDA has approved anthrax vaccine adsorbed (AVA;
BioThrax – Emergent BioSolutions) for prevention of
anthrax disease in adults following exposure to Bacillus
anthracis and intravenous anthrax immune globulin
(Anthrasil – Emergent BioSolutions) for treatment of
inhalation anthrax in adults and children. AVA has been
available since 1970 for prevention of anthrax disease
in persons at high risk of exposure.